QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stock-of-the-day-will-johnson--johnson-rally-the-sell-off-may-have-ended

Shares of Johnson & Johnson (JNJ) sold off on news regarding a dilution of its earnings. The selloff ended when it reach su...

 cantor-fitzgerald-reiterates-neutral-on-intra-cellular-therapies-maintains-132-price-target

Cantor Fitzgerald analyst Charles Duncan reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Neutral and maintains $132...

 johnson--johnson-stops-late-stage-depression-study-over-insufficient-efficacy

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato...

 mizuho-downgrades-intra-cellular-therapies-to-neutral-lowers-price-target-to-132

Mizuho analyst Graig Suvannavejh downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Outperform to Neutral and lowers the...

 needham-reiterates-hold-on-intra-cellular-therapiesto-hold

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) from Hold to Hold.

 intra-cellular-therapies-q4-eps-016-misses-011-estimate-sales-19922m-beat-19340m-estimate

Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.16) per share which missed the analyst consensus estima...

 axsomes-axs-05-in-alzheimers-agitation-could-be-billion-dollar-opportunity-says-analyst

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones a...

 canaccord-genuity-downgrades-intra-cellular-therapies-to-hold-raises-price-target-to-132

Canaccord Genuity analyst Sumant Kulkarni downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Hold and raises the ...

 rbc-capital-downgrades-intra-cellular-therapies-to-sector-perform-raises-price-target-to-132

RBC Capital analyst Brian Abrahams downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Outperform to Sector Perform and r...

 johnson--johnson-q4-earnings-cancer-drugs-performance-drives-revenue-beat-issues-strong-fy25-outlook

Johnson & Johnson's Q4 sales hit $22.52 billion, with strong growth in MedTech and oncology. 2025 guidance shows promis...

 microstrategy-sofi-technologies-and-carvana-are-among-top-large-cap-gainers-last-week-jan-13-jan-17-are-the-others-in-your-portfolio

These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, Mic...

 piper-sandler-downgrades-intra-cellular-therapies-to-neutral-raises-price-target-to-132

Piper Sandler analyst David Amsellem downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Overweight to Neutral and raises...

 intra-cellular-therapies-stock-is-surging-monday-whats-going-on

Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION